ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Nanobiotix SA

Nanobiotix SA (NBTX)

5.40
-0.15
(-2.70%)
Closed July 19 4:00PM
5.40
0.00
( 0.00% )
Pre Market: 4:00AM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
5.40
Bid
5.15
Ask
5.35
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Market Cap
Previous Close
5.40
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
47,133,328
Dividend Yield
-
PE Ratio
-5.66
Earnings Per Share (EPS)
-0.84
Revenue
36.21M
Net Profit
-39.7M

About Nanobiotix SA

Nanobiotix SA is a clinical-stage biotechnology company that focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. It develops NanoXray products to help patients receiving radiotherapy by magnifying ... Nanobiotix SA is a clinical-stage biotechnology company that focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. It develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its lead product candidate is NBTXR3, a preclinical research program for cancer immunotherapies. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Paris, Paris, Fra
Founded
1970
Nanobiotix SA is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker NBTX. The last closing price for Nanobiotix was $5.40. Over the last year, Nanobiotix shares have traded in a share price range of $ 0.00 to $ 0.00.

Nanobiotix currently has 47,133,328 shares outstanding. The market capitalization of Nanobiotix is $254.52 million. Nanobiotix has a price to earnings ratio (PE ratio) of -5.66.

NBTX Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SERVServe Robotics Inc
$ 11.36
(50.46%)
17.29M
RRRichtech Robotics Inc
$ 1.96
(33.33%)
8.61M
NCPLNetcapital Inc
$ 0.1275
(22.60%)
21.2M
SYTASiyata Mobile Inc
$ 0.7017
(21.40%)
1.21M
CISOCISO Global Inc
$ 0.7161
(20.35%)
1.56M
HUBCWHub Cyber Security Ltd
$ 0.0121
(-47.39%)
1.65k
XCURExicure Inc
$ 0.39
(-27.12%)
165.79k
VVOSVivos Therapeutics Inc
$ 2.05
(-16.33%)
1
SNTGSentage Holdings Inc
$ 2.14
(-13.71%)
20.48k
RYAAYRyanair Holdings PLC
$ 98.67
(-13.69%)
35.72k
NCPLNetcapital Inc
$ 0.1275
(22.60%)
21.2M
SERVServe Robotics Inc
$ 11.36
(50.46%)
17.29M
RRRichtech Robotics Inc
$ 1.96
(33.33%)
8.61M
MAXNMaxeon Solar Technologies Ltd
$ 0.2236
(3.71%)
2.89M
SQQQProShares UltraPro Short QQQ
$ 8.25
(-2.48%)
2.83M

NBTX Discussion

View Posts
Monksdream Monksdream 4 months ago
NBTX 10Q due 4/3
👍️0
Monksdream Monksdream 4 months ago
NBTX under $10
👍️0
Monksdream Monksdream 12 months ago
Nanobiotix SA NASDAQ: NBTX

GoSymbol lookup
Health Care : Biotechnology | Small Cap Value | Based in FranceCompany profile
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
This security is an American depositary receipt
ADR Fees
👍️0
Monksdream Monksdream 1 year ago
July 10, 2023
4:21 am ET
*Nanobiotix shares are trading higher after the company entered into a license agreement with Janssen Pharmaceutical for global co-development and commercialization of NBTXR3.
Benzinga
2:19 am ET
*Nanobiotix Enters License Agreement With Janssen Pharmaceutical For Worldwide Co-Development And Commercialization Of Potential First-In-Class Radioenhancer NBTXR3
Benzinga
Nanobiotix SA NASDAQ: NBTX

GoSymbol lookup
Health Care : Biotechnology | Small Cap Value | Based in FranceCompany profile
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
This security is an American depositary receipt
ADR Fees
👍️0

Your Recent History